Pharmacology/Pharmaceutical Industry
Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial
11 May, 2020 | 00:42h | UTCCommentaries: Interferon beta-1b for COVID-19 – The Lancet AND New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial – The Lancet AND A Drug Cocktail Hastens Recovery in Some Coronavirus Patients – The New York Times AND Triple drug therapy helps coronavirus patients recover more quickly, study finds – CNN AND Triple antiviral drug shows early promise in COVID-19 trial – Reuters AND Expert reaction to a study about a phase 2 trial of a triple antiviral drug combination treatment for COVID-19 – Science Media Centre
Preliminary Study Evaluates Interleukin-1 Blockade for Patients with Severe Covid-19
11 May, 2020 | 00:34h | UTCCommentaries: Expert reaction to study looking at use of arthritis drug anakinra in hospitalised patients with severe COVID-19 – Science Media Centre AND Small study of patients with severe COVID-19 treated with the arthritis drug anakinra finds clinical improvements – The Lancet
Revisited: Therapeutic and Toxic Blood Concentrations of More than 1100 drugs and Other Xenobiotics
11 May, 2020 | 00:15h | UTC
Position Paper: Antimicrobial Therapeutic Drug Monitoring in Critically Ill Adult Patients
11 May, 2020 | 00:19h | UTCCommentary: New antibiotic guidelines could save more lives in intensive care units – News Medical
Large Observational Study Finds Hydroxychloroquine Provides no Benefit in Hospitalized Patients with Covid-19
8 May, 2020 | 10:41h | UTCEditorial: The Urgency of Care during the Covid-19 Pandemic — Learning as We Go
Cohort Study: SLGT2 Inhibitors Linked to Lower Risk of Renal Events in Patients with Type 2 Diabetes
7 May, 2020 | 08:57h | UTCEditorial: SGLT2 inhibitors and kidney outcomes in the real world
Commentary: Certain diabetes drugs may protect against serious kidney problems – The BMJ
Related Analysis: Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators – The BMJ
Systematic Review: Chloroquine and Hydroxychloroquine as a Treatment for COVID‐19
6 May, 2020 | 03:44h | UTC“Pending further results from more extensive studies with more stringent study parameters, clinicians should defer from routine use of HCQ and CQ.”
COVID-19: Out-of-control Science and Bypassing Science-based Medicine
5 May, 2020 | 05:04h | UTCCOVID-19: Out-of-control science and bypassing science-based medicine – Science Based Medicine
Related: Covid-19 — A Reminder to Reason – New England Journal of Medicine AND Pandemic Science Out of Control – Issues in Science and Technology AND Science Has an Ugly, Complicated Dark Side. And the Coronavirus Is Bringing It Out – Mother Jones AND Against pandemic research exceptionalism – Science AND In Defense of Evidence-Based Medicine for the Treatment of COVID-19 ARDS – Annals of the American Thoracic Society
Study: In Utero Antidepressants and Neurodevelopmental Outcomes in Kindergarteners
5 May, 2020 | 03:47h | UTCIn Utero Antidepressants and Neurodevelopmental Outcomes in Kindergarteners – Pediatrics
Commentaries: Providing the Evidence for Managing Depression in Pregnancy – Pediatrics AND Adverse neurodevelopmental outcomes linked to prenatal exposure to antidepressants – 2 Minute Medicine
New Observational Studies Confirm the Safety of Renin–Angiotensin–Aldosterone System Blockers in Patients with Covid-19
3 May, 2020 | 22:32h | UTCStudy 3: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 – New England Journal of Medicine
Commentary: Blood Pressure Drugs Don’t Increase Coronavirus Risk, Studies Find – The New York Times
See also: Observational Study: Renin-Angiotensin System Inhibitors are Not Associated with Severity or Mortality in Hospitalized Patients with Coronavirus Disease (2 other studies on the subject)
Case Series: QT Intervals in Patients with COVID-19 Treated with Hydroxychloroquine Alone or in Combination with Azithromycin
3 May, 2020 | 22:01h | UTCCommentary: Beth Israel Deaconess Medical Center – Beth Israel Deaconess Medical Center
Related Studies: The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection – Circulation: Arrhythmia and Electrophysiology (link to abstract – $ for full-text) AND [Preprint] QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin – medRxiv
FDA Issues Emergency Use Authorization for the Use of Remdesivir to Treat COVID-19
3 May, 2020 | 22:03h | UTCSee also: Remdesivir: A Non-Antiviral Antiviral Drug? – Forbes
Small Observational Study Suggests Prophylactic LMWH Can Prevent COVID‐19 Disseminated Intravascular Coagulopathy
1 May, 2020 | 03:26h | UTCCOVID‐19 Coagulopathy in Caucasian patients – British Journal of Haematology
Treatment Considerations for COVID-19: A Critical Review of the Evidence
1 May, 2020 | 03:20h | UTC
[Abstract Only] Cohort Study: Effect of Hydroxychloroquine and Azithromycin on the QT Interval in Patients with Covid-19
1 May, 2020 | 03:10h | UTCThe Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection – Circulation: Arrhythmia and Electrophysiology (link to abstract – $ for full-text)
Perspective: Urging Caution on Remdesivir
1 May, 2020 | 03:07h | UTCUrging Caution On Remdesivir – Forbes
Related: About Remdesivir and About “Game-Changers” – Science Translational Medicine AND Conflicting Remdesivir Trial Results Released; Experts Urge More Research – Health Policy Watch AND Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation AND PulmCrit- First placebo-controlled RCT on remdesivir for COVID-19 – PulmCrit AND Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work? – The Guardian
“While I have enormous respect for the Institutes and their leaders, releasing the preliminary news without sharing the data behind it is highly irresponsible.”
Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
30 Apr, 2020 | 04:31h | UTCCommentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre
See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
Related Commentary on Twitter
With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw
— Carlos del Rio (@CarlosdelRio7) April 29, 2020
[Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
30 Apr, 2020 | 04:28h | UTCCommentaries: Hopes rise on coronavirus drug remdesivir – Nature AND The COVID-19 research news rollercoaster is running again: STAT News + Gilead’s remdesivir – HealthNews Review
See also: Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
[Abstract Only] Randomized Trial: Olaparib for Metastatic Castration-Resistant Prostate Cancer
30 Apr, 2020 | 03:38h | UTCOlaparib for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine
Systematic Review: Antidepressants for Smoking Cessation
29 Apr, 2020 | 04:40h | UTCAntidepressants for smoking cessation – Cochrane Library
Summary: Do medicines used to treat depression help people to quit smoking? – Cochrane Library
Closely Watched Arthritis Drug Disappoints as a Covid-19 Treatment, Studies Show
28 Apr, 2020 | 04:18h | UTCClosely watched arthritis drug disappoints as a Covid-19 treatment, studies show – STAT
Study: The QT Interval in Patients with COVID-19 Treated with Hydroxychloroquine and Azithromycin
26 Apr, 2020 | 21:18h | UTC
[Abstract Only] Randomized Trial: Clopidogrel Seems to Be a Better Choice for Patients > 70 years with Non-ST-elevation Acute Coronary Syndrome
26 Apr, 2020 | 21:14h | UTC
FDA Safety Alert: Risk of Heart Rhythm Problems with the use of Hydroxychloroquine or Chloroquine for COVID-19
26 Apr, 2020 | 21:20h | UTCNews Release: FDA warning for Hydroxychloroquine or Chloroquine for COVID-19: Risk of Heart Rhythm Problems – Outbreak News Today
Observational Study: Renin-Angiotensin System Inhibitors are Not Associated with Severity or Mortality in Hospitalized Patients with Coronavirus Disease
24 Apr, 2020 | 03:46h | UTCCommentary: Drugs for high blood pressure don’t appear to make COVID-19 worse – Science News